Founded in 2022, Genome Therapeutics (GTx) was formed to advance pioneering academic research from the laboratories of Professor Sir Shankar Balasubramanian at the University of Cambridge and Professor Samuel Aparicio at the University of British Colombia. GTx is developing novel therapies that target secondary DNA structures called G-quadruplexes (G4) that are overrepresented in cancer cells.
This novel approach to cancer therapeutics is underpinned by 25 years’ of academic research, paving the way for GTx to develop first-in-class therapies that precisely target the underlying genetic drivers of cancer and avoid the indiscriminate toxicity profile of classical chemotherapy agents.
Company Details
- Employees
- 9
- Founded
- -
- Address
- Lensfield Road, Yusuf Hamied,dept. Of Chemistry,united Kingdom
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.genometx.com/
- Keywords
- London.
- HQ
- Cambridge, England
Genome Therapeutics Questions
Genome Therapeutics's website is https://www.genometx.com/
Genome Therapeutics's LinkedIn profile is https://uk.linkedin.com/company/genometherapeutics
Genome Therapeutics has
9 employees.
View email and phone details for 9
employees at Genome Therapeutics.
Genome Therapeutics's industry is
Biotechnology Research
Genome Therapeutics's top competitors are
Pharmidex,
Invenirex,
Isomorphic Labs,
Rxbiologics,
Pharmaron,
Prima Mente,
Lex Diagnostics,
Orion Pharma,
Fairjourney Biologics,
Nuclera.
Genome Therapeutics's categories are Biotechnology Research
Genome Therapeutics's founding year is 2022
